Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05413759

RhEumatoid Arthritis MEDIcation Adherence

Led by Hospices Civils de Lyon · Updated on 2025-10-02

200

Participants Needed

2

Research Sites

287 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Rheumatoid arthritis (RA) is a public health issue because of its frequency, its functional consequences, the risk of morbidity and mortality and the costs incurred. A collaborative multiprofessional intervention initiated during hospitalization and continued after hospital discharge (ambulatory care ) would improve medication adherence in RA and therefore the health status of patients. Main objective: To compare, 12 months after the index hospitalization or consultation, the impact of pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician) on medication adherence to disease-modifying treatments of patients with RA compared to usual care without pharmaceutical care and specific multi-professional collaboration. Medication adherence to disease-modifying treatments will be assessed by the rate of coverage of disease-modifying treatments (or Medication Possession Ratio (MPR)). METHODOLOGY: Interventional, multicenter, controlled, randomized, open label study, comparing in parallel 2 groups of patients with rheumatoid arthritis initially hospitalized in a rheumatology department (pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician), initiated in the hospital and continued after hospital discharge (ambulatory care) vs traditional follow-up.

CONDITIONS

Official Title

RhEumatoid Arthritis MEDIcation Adherence

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with rheumatoid arthritis (RA)
  • Male or female aged 18 years or older
  • Hospitalized or had a consultation in a rheumatology department and returned home after discharge
  • Receiving disease-modifying antirheumatic drugs (DMARDs) for RA, including methotrexate, targeted synthetic DMARDs (JAK inhibitors), or subcutaneous biologic DMARDs
  • Able to manage own medication treatment independently
  • Understands and speaks French
  • Affiliated with French national health insurance or similar
  • Provided free, informed, and signed consent to participate
Not Eligible

You will not qualify if you...

  • Usual pharmacy already has or had a patient in the study's intervention group
  • Regular pharmacy currently treating another patient
  • Significant cognitive or psychiatric disorders incompatible with the study
  • Medication management at home done exclusively by a caregiver
  • Participating in another research that may interfere with study results
  • Adult under legal protection (Public Health Code)
  • Not fit to complete study follow-up
  • Pregnant or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Service de rhumatologie, Centre Hospitalier Lyon Sud, Groupement Hospitalier Sud, Hospices Civils de Lyon

Pierre-Bénite, Lyon, France, 69495

Not Yet Recruiting

2

Service de rhumatologie et pathologie osseuse - Hôpital Edouard Herriot

Lyon, France, 69003

Actively Recruiting

Loading map...

Research Team

R

Roland CHAPURLAT, MD/PHD

CONTACT

A

Audrey JANOLY-DUMENIL, PharmD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

HEALTH_SERVICES_RESEARCH

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here